Semaglutide vs Cagrilintide: GLP-1 Receptor Agonist vs Long-Acting Amylin Analog

Semaglutide is a GLP-1 receptor agonist with multiple regulatory approvals spanning type 2 diabetes, obesity, and cardiovascular risk reduction. Cagrilintide (AM833, NNC0174-0833) is a long-acting amylin receptor agonist that targets a structurally distinct receptor system in the brainstem and hypothalamus. The primary difference is pharmacological class: semaglutide is a GLP-1 receptor agonist, while cagrilintide is an amylin analog. Their distinct receptor systems are the rationale for studying them together as CagriSema.

For entity-first background before comparing the two pathways, start with the cagrilintide research overview and the semaglutide research overview. This page is research-educational and does not provide personal-use, dosing, treatment, or sourcing guidance.

Semaglutide vs Cagrilintide: Direct Comparison

Mechanism of Action: Side by Side

Semaglutide: GLP-1 Receptor Signaling

Semaglutide binds the GLP-1 receptor (GLP1R), a class B G-protein-coupled receptor. GLP1R couples to Gs proteins, driving adenylyl cyclase activation and cyclic AMP (cAMP) accumulation. Downstream PKA and EPAC2 activation produces glucose-dependent insulin secretion in pancreatic beta cells, glucagon suppression in alpha cells, slowed gastric emptying, and satiety signaling through hypothalamic arcuate and paraventricular nuclei. GLP1R is also expressed in the nucleus tractus solitarius, dopaminergic neurons of the substantia nigra, and microglia, explaining the neurological research programs. Two structural modifications underpin semaglutide’s pharmacokinetics: Aib substitution at position 8 prevents DPP-4 cleavage, and a C18 fatty diacid chain at lysine 26 enables albumin binding, extending the half-life to approximately 165-184 hours.

flowchart TD
    A["Semaglutide"] --> B["GLP-1 Receptor (GLP1R)\nClass B GPCR"]
    B --> C["Gs protein activation"]
    C --> D["Adenylyl cyclase / cAMP elevation"]
    D --> E1["Pancreatic beta cells\nGlucose-dependent insulin secretion"]
    D --> E2["Pancreatic alpha cells\nGlucagon suppression"]
    D --> E3["Hypothalamus / brainstem (NTS)\nSatiety signaling"]
    D --> E4["Gastric smooth muscle\nSlowed gastric emptying"]
    B --> F["Beta-arrestin\nReceptor internalization / biased signaling"]

Cagrilintide: Amylin Receptor Signaling

Cagrilintide is a 37-amino acid synthetic analog of human amylin, the peptide co-secreted with insulin by pancreatic beta cells. Amylin receptors are heterodimeric complexes of the calcitonin receptor (CALCR) and receptor activity-modifying proteins (RAMPs). Cagrilintide activates AMY1 (CALCR + RAMP1) and AMY3 (CALCR + RAMP3) expressed in the area postrema, nucleus tractus solitarius, and hypothalamic satiety circuits. A 2025 cryo-EM study resolved the structural basis of cagrilintide binding to both CALCR and amylin receptor complexes (PMID: 40204768, Nat Commun). A 2025 EBioMedicine study using receptor-subtype-selective antagonists in rodents confirmed that AMY1 and AMY3, rather than CALCR alone, mediate the body-weight-lowering effect (PMID: 40609154). Cagrilintide carries a C18 fatty acid chain via an eight-carbon linker at Lys-24, enabling the albumin-binding half-life extension to approximately six to eight days.

flowchart TD
    A["Cagrilintide"] --> B1["AMY1 Receptor\nCALCR + RAMP1"]
    A --> B2["AMY3 Receptor\nCALCR + RAMP3"]
    B1 --> C["cAMP signaling\nArea postrema / hypothalamus"]
    B2 --> C
    C --> D1["Satiety signals\nReduced food intake"]
    C --> D2["Glucagon suppression"]
    C --> D3["Slowed gastric emptying"]
    D1 --> E["Reduced body weight"]
    D2 --> E
    D3 --> E

The two receptor systems are anatomically overlapping but pharmacologically distinct. Amylin receptors are concentrated in the area postrema (a circumventricular organ lacking a blood-brain barrier), enabling direct peptide access. GLP1R is more broadly distributed across central and peripheral tissues. The distinct receptor systems provide the rationale for combination research. The Phase 1b trial tested the combination directly, but the clinical result should not be reduced to receptor anatomy alone (PMID 33894838).

Evidence Strength

Semaglutide: Extensive Clinical Evidence Across Multiple Indications

Semaglutide has the deepest clinical evidence base among GLP-1 receptor agonists. Key trial programs include:

Diabetes (SUSTAIN program): Eight Phase 3 trials evaluated subcutaneous semaglutide in type 2 diabetes. SUSTAIN-6 (NCT01720446, n=3,297) established cardiovascular safety and a signal for MACE reduction (HR 0.74, 95% CI 0.58-0.95; PMID 27633186, N Engl J Med 2016).

Obesity (STEP program): STEP 1 (NCT03548935, n=1,961) demonstrated a mean 14.9% body weight reduction versus 2.4% with placebo at 68 weeks (PMID 33567185, N Engl J Med 2021). STEP 5 confirmed sustained weight loss of approximately 15.2% at two years (PMID 36216945, Nat Med 2022).

Cardiovascular outcomes (SELECT trial): SELECT (NCT03574597, n=17,604) enrolled adults with obesity or overweight and established cardiovascular disease but without type 2 diabetes. Semaglutide 2.4 mg reduced the primary MACE composite by 20% versus placebo (HR 0.80, 95% CI 0.72-0.90; PMID 37952131, N Engl J Med 2023). This result produced a supplemental FDA approval for cardiovascular risk reduction in March 2024.

Chronic kidney disease (FLOW trial): FLOW (NCT03819153, n=3,533) enrolled adults with type 2 diabetes and CKD stages 2-4. Semaglutide 1 mg weekly reduced the composite kidney endpoint (sustained >=50% eGFR decline, kidney failure, cardiovascular death) versus placebo (HR 0.76, 95% CI 0.66-0.88; PMID 38785209, N Engl J Med 2024). The trial was stopped early for efficacy.

Heart failure (STEP-HFpEF): Semaglutide demonstrated improvements in KCCQ scores and 6-minute walk distance in heart failure with preserved ejection fraction. Consistent signals were seen in HFmrEF (PMID 39222642, Lancet 2024).

Neurodegeneration: Observational data link GLP-1 RA use to reduced Parkinson’s disease incidence (PMID 41994910). Mechanistic reviews document GLP-1R engagement reducing amyloid burden, tau pathology, and alpha-synuclein aggregation in preclinical models (PMID 40252880). Randomized neurodegeneration trials are ongoing.

Cagrilintide: Clinical Evidence Concentrated in Obesity and T2D

Cagrilintide’s evidence base is more focused, anchored in amylin pharmacology and metabolic studies. The cited publications and trial records describe it as investigational.

Phase 2 monotherapy (NCT03856047): A dose-ranging trial established the dose-response relationship for weight reduction versus liraglutide 3.0 mg and placebo over 26 weeks. This identified 2.4 mg once weekly as the Phase 3 dose.

Phase 2 CagriSema in T2D (PMID: 37364590, Lancet 2023): Mean HbA1c change at week 32 was -2.2 percentage points with CagriSema and -1.8 with semaglutide; the between-group HbA1c comparison was not statistically significant (p=0.075). Mean body-weight change was -15.6% and -5.1%, respectively (PMID 37364590).

REDEFINE 1 (NCT05567796; PMID 40544433): Randomized 3,417 adults without diabetes to cagrilintide-semaglutide, semaglutide, cagrilintide, or placebo. The treatment-policy estimand for mean body-weight change at week 68 was -20.4% with the combination and -3.0% with placebo.

REDEFINE 2 (NCT05394519; PMID 40544432): Randomized 1,206 adults with type 2 diabetes to cagrilintide-semaglutide or placebo. Mean body-weight change at week 68 was -13.7% and -3.4%, respectively. It did not include a semaglutide monotherapy arm.

Separate comparator studies: NCT06131437 compares CagriSema with tirzepatide in adults with obesity. NCT06065540 compares CagriSema with semaglutide, cagrilintide, and placebo in type 2 diabetes. Both registries are marked completed but do not post results, so this page does not attribute the REDEFINE 1 publication to either study.

Meta-analytic evidence: A 2026 systematic review and meta-analysis (PMID: 41834765, Diabetes Obes Metab) pooled trial estimates comparing CagriSema or cagrilintide with semaglutide. A separate systematic review and meta-analysis (PMID: 41759565, Am J Cardiol) pooled four randomized trials comparing CagriSema with semaglutide or placebo and reported outcomes for weight, waist circumference, systolic blood pressure, and gastrointestinal adverse events.

Cagrilintide’s published evidence is concentrated in the 2021-2025 period and remains narrower than semaglutide’s approval and outcome-trial record. There are no dedicated cardiovascular outcomes, CKD, or neurodegeneration trials for cagrilintide or CagriSema equivalent to the SELECT, FLOW, or Parkinson’s disease programs for semaglutide.

Safety Profiles

Shared Adverse Event Pattern

Both compounds produce an overlapping adverse event profile dominated by gastrointestinal effects: nausea (the most common complaint), vomiting, decreased appetite, and constipation. This similarity reflects convergent effects on gastric emptying and central satiety circuits, even though the receptor systems differ. Nausea is typically mild to moderate and attenuates with time in both compounds. Dose escalation protocols in clinical trials managed GI tolerability for both agents.

Semaglutide-Specific Safety Considerations

Semaglutide carries the GLP-1 receptor agonist class-level warnings:

• Thyroid C-cell tumors: Observed in rodent studies at suprapharmacological doses. The clinical relevance is uncertain, but semaglutide is contraindicated in individuals with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (MEN2).
• Pancreatitis: Current semaglutide labeling includes acute pancreatitis under warnings and precautions.
• Hypoglycemia: Semaglutide’s insulin secretion is glucose-dependent, minimizing intrinsic hypoglycemia risk. Combination with insulin or sulfonylureas increases risk.
• Gallbladder disease: Rapid weight loss with GLP-1 agents is associated with increased cholelithiasis. Semaglutide’s long-term STEP and SELECT data documented increased gallbladder-related adverse events.

Cagrilintide-Specific Safety Considerations

Cagrilintide’s safety data derive from Phase 1-3 trials and do not yet include the long-term post-marketing surveillance available for semaglutide.

• Combination safety evidence: REDEFINE 1 and 2 reported gastrointestinal events as the most common adverse-event cluster; most were transient and mild to moderate (PMID 40544433; PMID 40544432).
• Dedicated safety studies: QT, renal-impairment, and hepatic-impairment studies are registered as NCT05804162, NCT04209049, and NCT05564104. Their registry entries do not post results, so no QT or dose-adjustment conclusion is inferred here.
• Evidence gap: Cagrilintide does not have the post-approval surveillance depth available for semaglutide. Combination-trial safety cannot isolate every event to the cagrilintide component.
• Muscle composition: NCT07527195 evaluates body-composition and muscle outcomes across CagriSema, cagrilintide, and semaglutide study arms.

Practical Research-Context Differences

Receptor specificity: Researchers studying amylin biology, calcitonin receptor pharmacology, or area postrema satiety circuits have a specific reason to use cagrilintide. Researchers studying GLP-1 pathway biology, incretin physiology, or the cAMP-PKA axis in pancreatic or neuronal contexts will use semaglutide.

Evidence maturity: Semaglutide has approved products, outcome trials, and post-approval data. Cagrilintide has an investigational evidence base. That difference affects how strongly a study can connect a mechanistic finding to established human outcomes.

Combination studies: Cagrilintide is primarily studied in the context of CagriSema. Researchers designing combination studies that probe additive or synergistic satiety mechanisms are most likely to use cagrilintide as a complement to semaglutide or another GLP-1 agent, not as a standalone primary agent.

CNS and neurological models: Semaglutide has an active neurodegeneration research program supported by preclinical mechanistic data, epidemiological signals, and registered clinical trials. Cagrilintide’s CNS activity is concentrated in appetite-regulating nuclei. Researchers working on neuroinflammation, dopaminergic degeneration, or Alzheimer’s pathology would have clearer justification for semaglutide-based models.

Cardiovascular and renal models: Semaglutide has large-scale outcomes data (SELECT, FLOW, STEP-HFpEF) that ground cardiovascular and renal research programs. CagriSema has blood pressure findings from REDEFINE 1 secondary and post hoc analyses (PMID: 41328546), plus pooled systolic blood pressure findings from a separate four-trial systematic review and meta-analysis (PMID: 41759565), but no dedicated cardiovascular outcomes trial has been completed for cagrilintide.

Structural biology: Cagrilintide’s binding to amylin receptor complexes is structurally characterized by cryo-EM (PMID: 40204768). Researchers studying GPCR structural biology, RAMP-dependent pharmacology, or calcitonin family receptor activation mechanisms have specific reasons to work with cagrilintide. Semaglutide offers the more studied GLP1R structural pharmacology platform.

When Researchers Choose Semaglutide

Semaglutide is the appropriate primary agent when the research question requires:

• A GLP-1 receptor agonist pharmacology platform with extensive validation in human trials.
• Cardiovascular outcomes modeling: SELECT (PMID 37952131) and SUSTAIN-6 (PMID 27633186) provide benchmark data.
• Chronic kidney disease models: FLOW trial (PMID 38785209) establishes the evidence base.
• Neurodegeneration research: GLP1R expression in dopaminergic neurons and an active clinical trial program (PMID 41994910; PMID 40252880) provide preclinical and translational justification.
• Comparison against an approved reference standard: semaglutide’s regulatory approvals make it the canonical GLP-1 RA comparator in most study designs.
• Oral GLP-1 pharmacology: Only semaglutide has an approved oral formulation (Rybelsus/NDA 213051), enabling research into oral peptide delivery.

When Researchers Choose Cagrilintide

Cagrilintide is the appropriate primary agent when the research question requires:

• Amylin receptor biology: AMY1, AMY3, and CALCR-RAMP pharmacology are the defining research targets for cagrilintide.
• Area postrema satiety mechanisms: The area postrema’s role in cagrilintide-mediated weight reduction (established in PMID: 40609154) provides a model for circumventricular organ-mediated appetite regulation distinct from GLP-1 pathways.
• RAMP-dependent GPCR pharmacology: Cagrilintide’s cryo-EM structures (PMID: 40204768) offer structural data for AMY1 and AMY3 that have no equivalent in the GLP-1R literature.
• Additive satiety mechanism studies: Research designed to probe whether GLP-1 and amylin pathways produce additive, synergistic, or redundant weight effects benefits from having cagrilintide as a selective amylin arm to compare against semaglutide.
• CagriSema combination modeling: Understanding the pharmacodynamic interaction between amylin and GLP-1 receptor systems requires cagrilintide alongside semaglutide.
• Weight loss quality research: The 2026 muscle composition trial (NCT07527195) targets the question of lean mass preservation during weight loss, a mechanistic question that cagrilintide’s amylin receptor pathway may inform differently from GLP-1 pathways.

Closing Notes

Semaglutide and cagrilintide target different receptor families and are not mechanistically interchangeable. Phase 1b and Phase 2 studies directly compared combination and component arms, while REDEFINE 1 and 2 established Phase 3 combination-versus-placebo results in distinct populations. Those designs support complementary-pathway research without proving that every outcome is synergistic. The relevant research question is rarely “which compound?” but rather which pathway is under investigation and whether the amylin receptor system, the GLP-1 receptor system, or their interaction is the primary scientific question.

Semaglutide has the depth of regulatory, cardiovascular, renal, and neurological evidence appropriate for broad metabolic and multi-system research programs. Cagrilintide provides an amylin-receptor research model with human trial evidence in obesity and type 2 diabetes. CagriSema is a prominent clinical example of combining amylin and GLP-1 receptor pharmacology.

For foundational context on each compound, see the research hubs:

• Semaglutide Research Overview
• Cagrilintide as an amylin analog

Key References

• PMID 27633186: Marso SP et al. Semaglutide and Cardiovascular Outcomes in Type 2 Diabetes (SUSTAIN-6). N Engl J Med 2016.
• PMID 33567185: Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med 2021.
• PMID 33894838: Enebo LB et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of cagrilintide with semaglutide 2.4 mg. Lancet 2021.
• PMID 36216945: Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity (STEP 5). Nat Med 2022.
• PMID 37364590: CagriSema Phase 2 active-controlled trial in type 2 diabetes. Lancet 2023.
• PMID 37952131: Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). N Engl J Med 2023.
• PMID 38785209: Perkovic V et al. Semaglutide in Chronic Kidney Disease (FLOW). N Engl J Med 2024.
• PMID 39222642: Kosiborod MN et al. Semaglutide versus placebo in heart failure with mildly reduced or preserved ejection fraction. Lancet 2024.
• PMID 40204768: Structural characterization of cagrilintide binding to calcitonin and amylin receptors. Nat Commun 2025.
• PMID 40252880: Role of GLP-1 on amyloid, tau, and alpha-synuclein pathology. Neurosci Biobehav Rev 2025.
• PMID 40544432: REDEFINE 2, cagrilintide-semaglutide in adults with overweight or obesity and type 2 diabetes. N Engl J Med 2025.
• PMID 40544433: REDEFINE 1, cagrilintide-semaglutide in adults with overweight or obesity. N Engl J Med 2025.
• PMID 40609154: Cagrilintide body-weight effects through brain AMY1 and AMY3 receptors. EBioMedicine 2025.
• PMID 41328546: CagriSema and blood pressure outcomes: REDEFINE 1 secondary analysis. Hypertension 2026.
• PMID 41759565: CagriSema versus semaglutide monotherapy or placebo: systematic review and meta-analysis of randomized controlled trials. Am J Cardiol 2026.
• PMID 41834765: Systematic review and meta-analysis of cagrilintide and CagriSema weight outcomes. Diabetes Obes Metab 2026.
• PMID 41852165: Amylin receptor effects on skeletal muscle metabolism. 2026.
• PMID 41994910: GLP-1 RA use and Parkinson’s disease incidence: Scandinavian cohort. Diabetes Obes Metab 2026.

See also

Individual research hubs:

• Semaglutide research
• Cagrilintide research

Related comparisons:

• Semaglutide vs Retatrutide